NCT04006119View on ClinicalTrials.gov

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

August 5, 2021

Study Completion Date

August 5, 2021

Conditions
Glioblastoma
Interventions
BIOLOGICAL

Ad-RTS-hIL-12

"* intratumoral injection of Ad-RTS-hIL-12~* 2.0 x 10\^11 viral particles (vp) per injection"

DRUG

Veledimex

20mg/day 15 oral daily doses of veledimex

DRUG

Cemiplimab-Rwlc

Infusion every 3 weeks (350mg)

Trial Locations (7)

10016

NYU Langone Health, New York

32207

Baptist MD Anderson Cancer Center, Jacksonville

60611

Northwestern Memorial Hospital, Chicago

90048

Cedars Sinai, Los Angeles

94158

University of California - San Francisco, San Francisco

02115

Brigham and Women's, Boston

08820

JFK Medical Center, Edison

Sponsors
All Listed Sponsors
lead

Alaunos Therapeutics

INDUSTRY